Filing search / Ownership / COSCIENS Biopharma Inc. / Page 6

6-K

90eafics684ytrimyx

10 Mar 22

Current report (foreign)

6:21pm

6-K

gfibu

2 Mar 22

Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism

8:15am

6-K

ytplx 4uxg

26 Jan 22

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

4:29pm

6-K

gy3 fcmfqo

26 Jan 22

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities

4:24pm

6-K

6dcbkk2

23 Dec 21

Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

4:56pm

6-K

pbro akrzh2tr4un

4 Nov 21

Current report (foreign)

4:12pm

6-K

z85qg ompxjosinx

7 Oct 21

Current report (foreign)

8:00am

6-K

xlsei1ex

13 Sep 21

Current report (foreign)

7:00am

6-K

ic5q83e6d4

9 Sep 21

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

4:14pm

6-K

zlcizs

5 Aug 21

Current report (foreign)

12:00am

6-K

tq57l1 amo

29 Jul 21

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

8:15am

6-K

7md39 1qh7lyggb270s5

9 Jun 21

Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs

6:04am

6-K

dut6zcl010e

3 Jun 21

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

4:05pm

6-K

fv35df

17 May 21

Current report (foreign)

8:15am

6-K

bi4oo7mx9hi14 x40pl

13 May 21

Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

8:15am

6-K

b95yjuk 8l9

6 May 21

Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders

11:23am

6-K

ouures0ubmu1i0

6 May 21

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer

11:17am

6-K

erckko35bqd0 ti

6 May 21

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

11:12am

6-K

4u2 phkkyf

5 May 21

Condensed Interim Consolidated Financial Statements

12:00am